Arkolith/Insider Trading/RYTM/Form 4

Tetrault Lynn A.

DirectorRHYTHM PHARMACEUTICALS, INC. (RYTM) · full profile →Form 4 · filed Jun 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.7M
Net Open-Market Flow
-$3.7M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)37K$28.27$1.0M44K
Jun 22, 2026Sell(S)37K$100.32$3.7M7K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)37K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-077305) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML